Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

Embody vs MEDVidi

An in-depth comparison of two leading GLP-1 Providers

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
Embody logo

Embody

9.3
★★★★4.7/5

Best for: knowing which pharmacy fills the vial — it names RedRock Pharmacy

Visit Embody
VS

MEDVidi

4.4
★★☆☆☆2.2/5
Visit MEDVidi

Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, Embody starts at $79/mo, and Embody finishes ahead, 9.3 to 4.4. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.

Pricing

Embody

Injection — flat at every doseCompounded
$79/mo
semaglutide

Checkout: '$79/mo flat forever' (strikethrough $299); bundles $76/$73/$69 per month on 3/6/12-mo. CAVEAT: T&C list price is $199/mo — the $79 depends on the auto-applied SUMMER promo marketed as permanently locked; Trustpilot complaints allege the lock was not always honored.

Injection — flat at every doseCompounded
$129/mo
tirzepatide

Checkout tile 'Flat rate at $119/month (strikethrough $349)'; homepage 'starting at $129/month'; bundles $126/$123/$119 per month.

OralCompounded · oral
$229/mo
semaglutide

New oral semaglutide $229/mo.

Oral / gumCompounded · oral
$329/mo
tirzepatide

Oral tirzepatide $329/mo; gum bundles to $299/mo at 12-month.

MEDVidi

Pricing not publicly listed.

What’s included

Embody

Covered by the monthly price

Medication

In the price

Clinician visits

In the price

Shipping

In the price

Lab work

Not stated

Coaching

Not stated

MEDVidi

Covered by the monthly price

Medication

Charged on top

Clinician visits

In the price

Shipping

Charged on top

Lab work

Not stated

Coaching

Not stated

Score breakdown

Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.

Embody

9.3/10

Overall

MEDVidi

4.4/10

Value25%

10.0A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
5.0

User Experience15%

8.0A
vs
B
5.0

Trust & Safety15%

9.0A
vs
B
4.0

Accessibility10%

10.0A
vs
B
5.0

Support10%

7.0A
vs
B
5.0

Features & Coverage

FeatureEmbodyMEDVidi
Starting Price$79/mo
Features6 features6 features
States Available50Not disclosed
Compounded✓ Yes
Brand Name
FSA/HSA Accepted
FDA WarningsNoneNone

About Embody

Embody sells compounded semaglutide and tirzepatide by injection, plus a compounded oral tirzepatide gum that is unique in the category. Flat-rate pricing is aggressive, coverage runs to all 50 states, and clinician messaging is available 24/7 under a board-certified internal medicine CMO.

Read our full Embody review →

About MEDVidi

Each visit carries its own charge instead of a bundled subscription: 195 dollars to start, 159 dollars for a follow-up. Because the prescription travels to whichever pharmacy the patient picks, the drug is billed apart. Providers holding licenses evaluate patients and write phentermine, Qsymia and Saxenda alongside the brand-name Wegovy (semaglutide) and Zepbound (tirzepatide). The footprint is 33 states. Do not confuse the brand with MEDVi (medvi.com), which is a different one.

Read our full MEDVidi review →

Pros & Cons

Embody

What we like

  • Semaglutide at $79 a month, 58% below the $189 median for the same drug and form across this register
  • Tirzepatide at $129 a month, 52% below the $267 median for the same drug and form across this register
  • Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
  • The monthly figure covers medication, consult, shipping
  • Coverage is published for all 50 states
  • Names 4 dispensing pharmacies, which most sellers in this register do not do
  • No FDA warning letter matched this operator when we searched our enforcement register
  • Both oral and injectable options are on record, so the format is a choice rather than a condition

Watch-outs

  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

MEDVidi

What we like

  • The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
  • The monthly figure covers consult
  • No FDA warning letter matched this operator when we searched our enforcement register

Watch-outs

  • Billed separately from the monthly figure: medication, shipping
  • No state list is on record here, so whether it serves your state cannot be confirmed from this page
  • No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here

Our Verdict

Winner: Embody

Embody takes it, 9.3 against 4.4, and it is especially strong on knowing which pharmacy fills the vial — it names RedRock Pharmacy. MEDVidi is no weak second.

Choose Embody if…

You want knowing which pharmacy fills the vial — it names RedRock Pharmacy and an opening price near $79 a month.

Choose MEDVidi if…

You want broader feature coverage.

Ready to start? Vetted GLP-1 providers

Vetted telehealth providers that prescribe GLP-1 online.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.9

Oak

Semaglutide at $119/month, 37% under the register median

6.5

Direct Meds

Compounded semaglutide at $249/month

7.7

Try Ageless

Semaglutide at $119/month, 37% under the register median

Embody vs MEDVidi: FAQ

Glossary

The words sellers use, defined. Tap any term.

Continue exploring Embody and MEDVidi head-to-heads in the same category.

Or see the full category ranking.

Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.